Vor Biopharma Inc (VOR) - Total Liabilities
Based on the latest financial reports, Vor Biopharma Inc (VOR) has total liabilities worth $628.44 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Vor Biopharma Inc to assess how effectively this company generates cash.
Vor Biopharma Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Vor Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. Check Vor Biopharma Inc (VOR) asset resilience to evaluate the company's liquid asset resilience ratio.
Vor Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of Vor Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing Tianyishangjia New Material Corp Ltd
SHG:688033
|
China | CN¥2.48 Billion |
|
Wuhan Hiteck Biological Pharma Co Ltd
SHE:300683
|
China | CN¥393.09 Million |
|
Samsung Fire And Marine Ins Pref
KO:000815
|
Korea | ₩71.79 Trillion |
|
Nufarm Ltd
AU:NUF
|
Australia | AU$2.47 Billion |
|
Sok Marketler Ticaret As
IS:SOKM
|
Turkey | TL57.09 Billion |
|
South Plains Financial Inc
NASDAQ:SPFI
|
USA | $3.99 Billion |
|
Formosa International Hotels Corp
TW:2707
|
Taiwan | NT$5.43 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Vor Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Vor Biopharma Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vor Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vor Biopharma Inc (2018–2025)
The table below shows the annual total liabilities of Vor Biopharma Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $628.44 Million | +1259.46% |
| 2024-12-31 | $46.23 Million | -21.79% |
| 2023-12-31 | $59.10 Million | +21.22% |
| 2022-12-31 | $48.76 Million | +85.21% |
| 2021-12-31 | $26.33 Million | -4.74% |
| 2020-12-31 | $27.64 Million | +1164.27% |
| 2019-12-31 | $2.19 Million | -71.88% |
| 2018-12-31 | $7.77 Million | -- |
About Vor Biopharma Inc
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML… Read more